CVC Planning to Sell Another Chunk of Evonik

Speculation that German chemical producer Evonik is priming itself for a major acquisition or restructuring continues apace.

Following an announcement in February by the company's largest shareholder, the German coal mining drawdown fund RAG, that it was increasing equity by €400 million through the issue of a bond with maturity in 2021, Evonik's other major shareholder, private equity fund CVC this week said it would unload a further 2 million shares valued at €700 million.

With the deal, the fund will reduce its stake in Evonik by about a third, from 14% to 9.4%. J.P. Morgan and Bank of America Merrill Lynch are handling the sale of the shares, which are priced at €31.85 each.

In March, taking advantage of a 15% rise in Evonik's share price over the preceding three months, CVC sold shares worth 3.9% of the German company's equity, but netted a disappointing €29.15 per share.

RAG, which owns 68% of Evonik, has stressed that it does not divest any shares, but plans to remain a long-term shareholder. In the past, the coal fund had said it would reduce its engagement gradually to diversify its portfolio.

The fund, which evolved out of a former coal mining company, is responsible for footing the bill for Germany's exit from coal mining up to 2018.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.